Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.19
    -0.08 (-1.87%)

    Market Cap: $949.85M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Prime Medicine, Inc. Common Stock (PRME) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Prime Medicine, Inc. Common Stock are Rigel Pharmaceuticals (RIGL), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA). By market cap, Prime Medicine, Inc. Common Stock ranks 4th of the 13 companies on this page; Precigen (PGEN) is the largest at $1.63B. The median P/E of the 3 companies with a P/E is 39.3x.

    Peer Comparison

    PRME's revenue growth of 243.9% is above the peer median of 8.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Intellia Therapeutics Inc (NTLA)$1.36BN/A26.1x0.0%-50.0%-48.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    OmniAb Inc. (OABI)$716.17MN/A15.7x-108.1%-17.5%78.3%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Sana Biotechnology Inc (SANA)$605.26MN/AN/A0.0%-46.8%0.0%0.00%
    Design Therapeutics Inc (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Peer median$693.32M39.3x5.6x0.0%-28.5%8.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Prime Medicine, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors
    Intellia Therapeutics Inc (NTLA)
    Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
    NTLA competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    OmniAb Inc. (OABI)
    OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform.
    OABI competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Sana Biotechnology Inc (SANA)
    Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
    SANA competitors
    Design Therapeutics Inc (DSGN)
    Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
    DSGN competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors

    Frequently Asked Questions About PRME

    Who are Prime Medicine, Inc. Common Stock's main competitors?

    The companies most similar to Prime Medicine, Inc. Common Stock include Rigel Pharmaceuticals (RIGL), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Neurogene (NGNE) and Precision BioSciences (DTIL), listed from the closest match.

    Who is Prime Medicine, Inc. Common Stock's biggest competitor?

    Precigen (PGEN) is the largest of the similar companies at $1.63B; Rigel Pharmaceuticals (RIGL) is the closest match by business profile, size, sector and industry.

    How does PRME stock compare with its competitors?

    PRME's P/S is 105.5x against a peer median of 5.6x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Prime Medicine, Inc. Common Stock's competitors pays a higher dividend?

    Prime Medicine, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Prime Medicine, Inc. Common Stock bigger than its competitors?

    No. Prime Medicine, Inc. Common Stock is 4th by market cap among the 13 companies on this page; the largest is Precigen (PGEN) at $1.63B.